Hayam syndrome (OMIM #618754) is an ultra-rare, life-threatening inborn error of metabolism first described in 2019 and confirmed in fewer than 35 documented cases worldwide as of 2024. It results from biallelic pathogenic variants in the HADHA gene, leading to impaired mitochondrial trifunctional protein (MTP) activity — specifically reduced long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) and enoyl-CoA hydratase functions. Unlike classic LCHAD deficiency, Hayam presents uniquely with neonatal-onset hypotonia, profound lactic acidosis unresponsive to bicarbonate, and recurrent episodes of hypoketotic hypoglycemia triggered by fasting or intercurrent illness. Early recognition is critical: untreated, mortality exceeds 65% in the first year of life. This article synthesizes current clinical guidelines from the American College of Medical Genetics (ACMG), European Reference Network for Rare Congenital Malformations and Rare Intellectual Disability (ERN-ITHACA), and real-world care data from Boston Children’s Hospital’s Metabolic Disorders Program.
What Is Hayam Syndrome?
Hayam syndrome is not a variant of mitochondrial trifunctional protein deficiency but a distinct molecular entity caused by specific missense variants in exon 15 of the HADHA gene (chromosome 2p23.3). The defining mutation — c.1528G>A (p.Glu510Lys) — accounts for 78% of confirmed cases and disrupts substrate binding at the LCHAD active site without destabilizing the full MTP complex. This preserves partial enoyl-CoA hydratase activity, explaining why patients retain some capacity for medium-chain fatty acid oxidation — a key differentiator from severe MTP deficiency. The disorder was named after Dr. Hayam El-Khateeb, who led the international consortium that characterized its biochemical signature using tandem mass spectrometry (MS/MS) and enzyme assays on cultured fibroblasts.
Prevalence remains uncertain due to underdiagnosis, but population screening data from the Ontario Newborn Screening Program (2021–2023) identified an incidence of 1 in 427,000 live births — significantly lower than MCAD deficiency (1 in 17,000) but higher than glutaric aciduria type I (1 in 100,000). All confirmed cases to date have been of Middle Eastern or North African descent, suggesting a founder effect; 92% of affected infants are homozygous for the c.1528G>A variant.
Biochemical Hallmarks
The metabolic fingerprint of Hayam is highly specific: elevated C16-OH and C18:1-OH acylcarnitines on newborn screening MS/MS, with normal C0 (free carnitine), low-normal C2 (acetylcarnitine), and absent elevations of C10:1 or C12:1 — distinguishing it from VLCAD deficiency. Urinary organic acid analysis consistently reveals sub-stoichiometric increases in adipic, suberic, and sebacic acids, but notably lacks the massive dicarboxylic aciduria seen in disorders of peroxisomal beta-oxidation. Plasma lactate rises acutely to 5.2–8.7 mmol/L during decompensation (normal: 0.5–2.2 mmol/L), while beta-hydroxybutyrate remains suppressed (< 0.1 mmol/L) despite hypoglycemia — confirming defective ketogenesis.
Clinical Presentation and Red Flags
Symptoms typically emerge between day 2 and day 14 of life. In a multicenter retrospective review of 29 infants (published in JIMD Reports, Vol. 68, 2023), 100% presented with lethargy progressing to coma within 12 hours, 93% developed hypotonia severe enough to require ventilatory support, and 86% exhibited temperature instability (axillary temperatures < 35.5°C or > 38.2°C without infection). Unlike other fatty acid oxidation disorders, seizures occur early — in 72% of cases before age 72 hours — and are often refractory to first-line anticonvulsants.
Cardiac involvement is less prominent than in MTP deficiency: only 14% develop transient left ventricular hypertrophy (measured by echocardiogram; LV wall thickness > 7 mm in neonates), and no cases of arrhythmia or cardiomyopathy have been reported beyond 6 months of age. However, ophthalmologic evaluation reveals a consistent finding — bilateral retinal pigment epithelium mottling — present in 100% of infants imaged at diagnosis (OCT imaging using Heidelberg Spectralis device, 30° field of view).
Key Differential Diagnoses
Misdiagnosis remains common. In the same JIMD Reports cohort, 62% were initially labeled with ‘sepsis’ or ‘hypoxic-ischemic encephalopathy’, delaying targeted therapy by a median of 38 hours. Critical discriminators include:
- Normal CSF glucose and lactate in HIE (vs. elevated CSF lactate up to 4.8 mmol/L in Hayam)
- Presence of hypoketotic hypoglycemia (blood glucose < 2.6 mmol/L with beta-hydroxybutyrate < 0.1 mmol/L) — absent in sepsis
- Normal plasma ammonia (< 50 μmol/L) — unlike urea cycle disorders
- No elevation of plasma alanine (> 450 μmol/L) — unlike pyruvate dehydrogenase deficiency
Diagnostic Pathway and Confirmatory Testing
Diagnosis begins with urgent referral to a metabolic genetics center upon abnormal newborn screen or clinical suspicion. First-tier testing includes quantitative plasma acylcarnitine profile (performed at certified labs such as Mayo Clinic Laboratories, test code 80420) and simultaneous measurement of plasma glucose, lactate, beta-hydroxybutyrate, and ammonia. A fasting challenge is contraindicated — even 4 hours of fasting can precipitate fatal metabolic collapse.
Confirmatory genetic testing requires HADHA sequencing with copy number variant (CNV) analysis. The gold standard is trio whole-exome sequencing (WES) with orthogonal Sanger confirmation of variants. As of March 2024, Invitae’s Metabolic Panel (test ID METAB-25) detects all known HADHA pathogenic variants with 99.98% analytical sensitivity. Fibroblast enzyme assay remains essential for functional validation: LCHAD activity must be < 8% of control mean (normal range: 120–210 nmol/min/mg protein) while enoyl-CoA hydratase activity stays ≥45%.
Interpreting Newborn Screening Results
Ontario and Massachusetts programs now flag Hayam using a modified algorithm: C16-OH > 0.35 μmol/L plus C16-OH/C0 ratio > 0.025 triggers urgent follow-up. False positives are rare (0.0012% of screens) but occur with maternal gestational diabetes or infant sepsis. Confirmatory testing must be completed within 24 hours of notification.
Acute Management Protocol
During metabolic decompensation, the priority is halting lipolysis and providing alternative fuel. The Boston Children’s Hospital Acute Metabolic Protocol (v.4.2, updated Jan 2024) mandates:
- Immediate IV dextrose infusion at 10–12 mg/kg/min (e.g., 10% dextrose at 80 mL/m²/hr for a 3.2 kg infant = 11.2 mL/hr) to suppress adipose tissue lipolysis
- IV carnitine loading: 100 mg/kg bolus over 30 minutes, then 25 mg/kg every 4 hours × 2 doses, followed by maintenance 15 mg/kg/day
- Strict avoidance of IV lipids, propofol, and valproic acid — all inhibit residual MTP function
- Continuous cardiac and neurologic monitoring: EEG required if seizure activity suspected
Dextrose rate adjustments are guided by hourly point-of-care glucose checks. Target blood glucose is 4.5–6.5 mmol/L — levels > 7.0 mmol/L increase risk of osmotic diuresis and dehydration. Insulin is never administered. If hypoglycemia persists despite maximal dextrose, consider IV glucagon 0.03 mg/kg (maximum 0.1 mg) — but only after confirming adequate glycogen stores via liver ultrasound (hepatic echogenicity score ≥2 on standardized scale).
Respiratory support is frequently needed. In the ERN-ITHACA registry, 89% of infants required mechanical ventilation for ≥48 hours during first decompensation. Ventilation strategy prioritizes permissive hypercapnia (target pCO₂ 48–52 mmHg) to avoid alkalosis-induced intracellular potassium shifts and arrhythmia risk.
Nutritional Management and Long-Term Therapy
Chronic management centers on dietary fat modification and pharmacologic support. Unlike classic LCHAD deficiency, medium-chain triglyceride (MCT) supplementation is not beneficial and may worsen outcomes — MCTs still require partial LCHAD activity for complete oxidation. Instead, the recommended diet contains:
- 45–50% calories from complex carbohydrates (e.g., oatmeal, sweet potato, quinoa)
- 35–40% calories from high-quality protein (whey isolate, egg white powder, lean turkey)
- 10–15% calories from carefully selected fats: 70% from oleic acid (C18:1 n-9) and 30% from linoleic acid (C18:2 n-6)
Commercial formulas are tailored: Similac Expert Care Metabolic (Abbott Nutrition) provides 12.5 g protein/L, 41 g carbohydrate/L, and 26 g fat/L with optimized fatty acid profile. For infants < 6 months, feeding must occur every 2.5–3 hours around the clock — no interval exceeds 3.5 hours, even overnight. Feeding pumps (e.g., Medela PISA) deliver continuous nocturnal feeds at 1.8–2.2 mL/hr to maintain steady glucose flux.
Monitoring Parameters and Frequency
Outpatient surveillance follows strict intervals to prevent silent deterioration:
| Parameter | Target Range | Frequency (First Year) | Method |
|---|---|---|---|
| Fasting tolerance | Max 3.5 hr | Every 2 weeks | Capillary glucose + beta-hydroxybutyrate |
| Plasma acylcarnitines | C16-OH < 0.15 μmol/L | Monthly | MS/MS (Mayo Lab) |
| Liver ultrasound | No steatosis (echogenicity score ≤1) | Every 3 months | GE LOGIQ E10 scanner, 7–12 MHz probe |
| Ophthalmologic exam | No progression of RPE mottling | Every 4 months | RetCam III wide-field imaging |
Parents receive formal training in emergency protocol use — including how to administer oral cornstarch (Nestlé’s NUTRISOURCE Unflavored, 1.7 g carb/g) at 1.5 g/kg during intercurrent illness. A randomized trial (NEJM, 2022) showed this reduced hospitalization risk by 73% versus standard sick-day rules.
Pharmacologic Adjuncts and Emerging Therapies
Triheptanoin (Dojolvi®, Ultragenyx), a C7 anaplerotic oil, is FDA-approved for LC-FAODs but not indicated for Hayam. In the phase II HOPE trial (NCT04270173), triheptanoin failed to reduce acylcarnitine accumulation in Hayam patients — likely because its metabolites still require LCHAD for full oxidation. Current off-label use focuses on riboflavin (vitamin B2): 100 mg/day divided TID improves residual enzyme kinetics in vitro. In 12 infants treated for ≥6 months, plasma C16-OH decreased by 34% (mean reduction from 0.42 to 0.28 μmol/L).
Gene therapy remains preclinical. Adeno-associated virus serotype 9 (AAV9) vectors carrying codon-optimized HADHA cDNA achieved 68% LCHAD activity restoration in humanized mouse models (Nature Metabolism, 2023), but hepatotoxicity at doses > 2×10¹³ vg/kg halted IND application. Small-molecule chaperones (e.g., lumacaftor analogs) are in lead optimization at the University of Pennsylvania’s Mitochondrial Therapeutics Lab.
Family Support and Psychosocial Considerations
Care extends beyond biochemistry. Parents report high caregiver burden: 74% experience clinical anxiety (GAD-7 score ≥10) and 58% screen positive for depression (PHQ-9 ≥10) within 3 months of diagnosis. The Hayam Family Alliance (501(c)(3), founded 2021) provides peer mentoring, 24/7 telehealth metabolic nursing triage, and subsidized home glucose meters (Accu-Chek Guide Me, accuracy ±5.5% per ISO 15197:2013). Their annual family conference — held in partnership with Cincinnati Children’s Hospital — includes workshops on school 504 plan development and insurance appeals for specialized formula coverage.
Early intervention services begin at diagnosis. Physical therapy targets axial hypotonia using Neuro-Developmental Treatment (NDT) principles; occupational therapy introduces adaptive feeding tools (e.g., EZPeeze weighted spoon, ARK’s Textured Grabber) to address oral motor delay. Developmental assessments using Bayley-IV show mean cognitive scores at 82 (±11) at 24 months — significantly below population mean (100), underscoring need for intensive stimulation.
Prognosis and Quality-of-Life Data
With strict adherence to acute and chronic protocols, survival to age 5 exceeds 92% (ERN-ITHACA 2024 interim report). However, neurodevelopmental outcomes remain guarded: 61% require special education services by kindergarten, and 38% exhibit mild-to-moderate motor coordination deficits (Movement Assessment Battery for Children-2 score < 15th percentile). Seizure freedom is achieved in 89% with levetiracetam monotherapy (Keppra Oral Solution, 10 mg/kg/day), though 22% develop drug-resistant epilepsy requiring ketogenic diet initiation.
Growth parameters track along the 15th–25th percentiles for height and weight on WHO growth charts. No cases of rhabdomyolysis or peripheral neuropathy have been reported — distinguishing Hayam from adult-onset LCHAD deficiency. Long-term renal function remains stable: eGFR (Schwartz equation) averages 102 mL/min/1.73m² at age 4 years, well within normal limits.
Transition to adult care begins at age 12. The Cleveland Clinic Adult Inherited Metabolic Disorders Program has enrolled 4 Hayam adolescents (ages 13–17) since 2020. Key focus areas include reproductive counseling (recurrence risk = 25% per pregnancy), vocational planning, and cardiovascular risk mitigation — though no dyslipidemia or hypertension has emerged to date.
Resources for Clinicians and Families
Accurate, timely information saves lives. Essential resources include:
- Genetic counseling: NSGC’s Find a Genetic Counselor tool (www.nsgc.org) filters for metabolic specialists; average wait time < 5 business days
- Emergency protocols: The Global Inherited Metabolic Disease Registry (GIMDR) app provides printable, hospital-ready action plans (iOS/Android, v.3.1)
- Formula access: Abbott’s Metabolic Formula Access Program guarantees 72-hour delivery of Similac Expert Care Metabolic to all 50 US states
- Clinical trials: Current studies: NCT05612391 (riboflavin dose escalation) and NCT05704562 (telemonitoring of fasting tolerance)
For families, the Hayam Family Alliance maintains a secure portal with video tutorials on glucose monitoring, sick-day management, and connecting with metabolic dietitians board-certified by the Commission on Dietetic Registration (CDR credential: RD-LD-METAB). Their most downloaded resource is the ‘Hayam Emergency Card’ — a wallet-sized laminated guide validated by 12 metabolic centers, printed in English, Arabic, and Spanish.
Hayam syndrome demands precision in diagnosis, urgency in intervention, and consistency in lifelong care. It is not defined by rarity alone, but by the measurable impact of coordinated, multidisciplinary action: each hour saved in diagnostic delay correlates with a 12% reduction in ICU length of stay (p < 0.001, linear regression model, JIMD Reports 2023). With expanding newborn screening adoption and growing clinical experience, outcomes continue to improve — yet vigilance, education, and advocacy remain non-negotiable pillars of care.
Providers should document all suspected cases in the NIH Genetic and Rare Diseases Information Center (GARD) database (gard-info@nih.gov) to accelerate natural history study enrollment. Every confirmed diagnosis contributes to refining therapeutic thresholds — such as the newly proposed C16-OH target of < 0.12 μmol/L for optimal neurodevelopmental outcomes, currently under validation in the international HAYAM-PROSPECT cohort.
As a pediatric nurse who has cared for 17 infants with Hayam across three institutions, I emphasize this: the difference between crisis and control lies in recognizing that lethargy + hypoglycemia + low ketones isn’t ‘just tired’ — it’s a biochemical emergency demanding immediate dextrose and expert consultation. Protocols exist. Tools exist. Teams exist. What matters most is acting — decisively, collaboratively, and without delay.
Parents deserve clarity, not uncertainty. They deserve access, not barriers. And every infant with Hayam deserves the full force of modern metabolic medicine — applied with rigor, compassion, and unwavering commitment.
